The artificial intelligence sector continued to attract significant attention in 2025. Data analytics platform Palantir Technologies (PLTR) saw its stock price surge by 130%, making it one of the best-performing AI stocks. However, the health insurance sector performed weakly, with UnitedHealth Group (UNH) experiencing a 36% plunge in its stock price year-to-date, making it the worst-performing component of the Dow Jones Industrial Average. Against the backdrop of a polarized market, Warren Buffett’s Berkshire Hathaway chose to buy on the dip, increasing its stake in UnitedHealth Group by approximately 5 million shares. Analysis suggests that Palantir’s historic rally may face challenges, while UnitedHealth Group’s current difficulties might be breeding investment opportunities.
The AI revolution has undoubtedly been a powerful catalyst for Palantir’s business growth. Over the past three years, its AI-based software suites, including the Foundry, Apollo, and Gotham platforms, have experienced exponential demand from both government agencies and private enterprises. The company’s achievement of profitability further demonstrates the market appeal of its AI products. These positive and continuously improving unit economics have helped it stand out in competition against giants like Salesforce and SAP.
However, concerns about Palantir primarily focus on its valuation. Palantir’s price-to-sales ratio is not only 114 times higher than that of many leading software peers, but its expansion pace is also quite staggering. This soaring valuation implies that investors hold extremely high, perhaps even unrealistic, expectations for the company. In the long run, even if the company’s quarterly performance far exceeds expectations, it faces the risk of failing to meet these overly optimistic projections, which could lead to a prolonged sell-off in the stock. Furthermore, its current valuation multiples far exceed levels seen during the late-1990s dot-com bubble. This correlation might be precisely what prompts investors like Michael Burry to short the stock. Although Palantir could still be a long-term winner in the AI revolution, its stock price faces the risk of a significant correction due to valuation reassessment, potentially taking years to recover to current levels.
UnitedHealth Group’s performance decline began with a downward revision of its financial guidance earlier this year, primarily for two reasons: first, higher-than-expected utilization rates in its Medicare Advantage business; second, challenges faced by its pharmacy and healthcare services subsidiary, Optum Health, including lower participation in certain markets and higher-than-anticipated patient costs due to Medicare funding cuts. Although it might take several quarters for investors to see an acceleration in revenue and profit growth, the current stock price decline may have already overdiscounted these negatives. The company’s P/E ratio of 16.8 is near a five-year low. Considering it still provides essential health insurance services, such a drastic valuation plunge appears somewhat exaggerated.
Moreover, UnitedHealth Group is likely to become an invisible beneficiary of AI in the coming years. Large language models can scan medical bills and process vast amounts of constantly changing laws and regulations in real-time, helping to predict critical business metrics such as healthcare service utilization by region and age group. During the stock price slump, company insiders joined Buffett in increasing their holdings. The expectation of a turnaround, insider buying, institutional endorsement from Berkshire Hathaway, and the potential benefits from AI collectively create conditions for UnitedHealth Group’s future recovery.
As of the time of writing, UnitedHealth Group’s market capitalization is $291 billion, approximately 43% lower than Palantir’s. Behind this significant market cap gap lies the difference in their investment logic. UnitedHealth Group currently faces more reasonable investor expectations and benefits from long-term macroeconomic tailwinds, which could drive valuation expansion in the future. In contrast, Palantir’s stock price is at an unsustainable high, seemingly under constant pressure for a correction. Therefore, in the current market environment, UnitedHealth Group’s stock offers both growth potential and a margin of safety, making it undoubtedly an investment opportunity worth watching for investors looking toward 2030 and beyond.
